SANTA CLARA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced fourth quarter and full year fiscal 2026 financial results for the period ended January 31, 2026. Revenue for the fourth quarter of fiscal 2026 was $100.9 million, up 20.1% from $84.0 million in the same period in fiscal 2025. For the fiscal year ended January 31, 2026, revenue was $390.7 million, up 37.2% from $284.9 million for the fiscal year ended January 31, 2025.Gros ...

CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth ...

Company achieves record 7.5 million pounds of PureFive® production in Q4; appoints Donald Carpenter as CFO; progresses Gen-2 design showing path to costs below virgin polypropyleneORLANDO, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PureCycle Technologies, Inc. (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, today, announced results for the fourth quarter and fiscal year ending December 31, 2025. Fourth Quarter 2025 Highlights Operations Produced record 7.5 million pounds of PureFive® rPP ...

Fourth quarter and full year 2025 revenue exceeded guidanceFRAMINGHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue was $61.5 million, a decrease of 1% from $62.3 million in Q4 2024.Net Loss, inclusive of goodwill impairment charge ...

Board of Directors Declared Total Dividends of $0.52 per Share for First Quarter 2026 Base Dividend of $0.43 and Supplemental Dividend of $0.09 Per Share EVANSTON, Ill., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Fidus Investment Corporation (NASDAQ:FDUS) (“Fidus” or the “Company”), a provider of customized debt and equity financing solutions, primarily to lower middle-market companies based in the United States, today announced its financial results for the fourth quarter and full year ended December 31, 2025. Four ...

Record full year 2025 revenue of $236.3 million increased 15% compared to prior yearOperating Cash flow improvement of $22 million in full year 2025Generated $10 million of free cash flow in the fourth quarter, the first quarter of positive free cash flow in Company history WARSAW, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial resu ...

Core Insights - TTEC Holdings, Inc. reported a net loss of $170.5 million in Q4 2025, primarily due to a non-cash goodwill impairment charge of $205.4 million, despite a slight revenue increase of 0.4% to $570.0 million [2][4][9] - For the full year 2025, the company experienced a revenue decline of 3.2% to $2.137 billion, with a net loss of $185.1 million, although non-GAAP net income was $52.8 million, representing 2.5% of revenue [3][4][13] - The company is optimistic about 2026, projecting revenue between $2.005 billion and $2.055 billion, with a focus on improving EBITDA and operating income margins [19][20] Financial Performance - Q4 2025 revenue was $570.0 million, up 0.4% from $567.4 million in Q4 2024, with a positive foreign exchange impact of $4.0 million [9] - Adjusted EBITDA for Q4 2025 was $62.2 million, or 10.9% of revenue, compared to $50.9 million, or 9.0% of revenue in the prior year [8][9] - Full year 2025 adjusted EBITDA was $213.7 million, or 10.0% of revenue, an increase from $202.3 million, or 9.2% of revenue in 2024 [11][13] Segment Performance - TTEC Digital reported Q4 2025 revenue of $125.5 million, a 9.2% increase year-over-year, but faced a significant loss from operations of $200.0 million [21] - TTEC Engage had Q4 2025 revenue of $444.5 million, a 1.8% decrease from the previous year, but improved its income from operations to $27.4 million, or 6.2% of revenue [21] Cash Flow and Balance Sheet - Cash flow from operations in Q4 2025 was positive at $2.6 million, a recovery from a negative $1.1 million in Q4 2024, with full year cash flow from operations at $121.1 million compared to a negative $58.8 million in 2024 [14] - As of December 31, 2025, TTEC had cash and cash equivalents of $82.9 million and total debt of $908.0 million, resulting in a net debt position of $825.1 million [14][15] Business Outlook - The company aims to enhance its EBITDA and operating income in 2026, with a commitment to higher value transformational engagements across its segments [19][20] - TTEC's guidance for 2026 includes projected revenue of $2.030 billion and non-GAAP adjusted EBITDA of $230 million, indicating a focus on margin expansion [20][22][23]

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year ...

LYNNWOOD, Wash., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Zumiez Inc. (NASDAQ: ZUMZ) today announced it will report fiscal 2025 fourth quarter and full year results on Thursday, March 12, 2026, following the closing of regular stock market trading hours. The Company will hold a conference call that day at 5:00 p.m. ET to review the results. To access the conference call, please pre-register using this link (Registration Link). Registrants will receive confirmation with dial-in details. The conference call will als ...

2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outst ...